People currently taking all forms of the recently suspended drug Avandia (Rosiglitazone) have until 21 October to be reviewed and transferred onto an alternative treatment.
Anyone currently taking the drug who has not yet consulted their healthcare professional should make an appointment without delay in order to discuss their alternative treatment arrangements.
Following the European Medicines Agency’s (EMA) recommendation to suspend all forms of Rosiglitazone from the European market on 23 September 2010, Avandia / Avandamet will not be available in the UK after 21 October 2010. From this date all stocks will be recalled.
To ensure people are smoothly transferred onto an alternative treatment, prescribers are being encouraged to put in place a system that ensures each person is reviewed and changed to another suitable treatment as soon as possible.
Any adverse side effects experienced by someone taking a rosiglitazone-containing product should be reported to theMedicines and Healthcare Products Regulatory Agency(MHRA).
Diabetes UK advice
Diabetes UK is advising anyone currently taking Avandia or Avandamet to consult their healthcare team without delay to discuss switching onto an alternative treatment that is best suited to their needs.
People currently taking these tablets should not stop taking their medication in the meantime, unless they are experiencing adverse side effects (such as swollen ankles or breathlessness), as it is very important that people with diabetes keep their blood glucose under control to prevent short and long term complications.